Acute myeloid (myelogenous, myelocytic) leukemia (AML) is a rapidly progressing blood cancer with an extremely poor overall prognosis. AML predominantly affects the elderly population and this subgroup of patients has an exceptionally high level of unmet needs. GlobalData estimates the 2014 sales for AML at approximately $342 million across the 7MM covered in this report. The market will increase by almost three-fold over the forecast period, reaching $932 million in 2024 at a CAGR of 10.5%. This growth will be driven by an increase in incident cases of AML as well as the approval and uptake of premium-priced products, such as FLT3 kinase inhibitors (quizartinib and midostaurin), a PI3 kinase inhibitor (volasertib) and new formulations of existing chemotherapies such as Vyxeos (CPX-351), guadecitabine and CC-486. GlobalData expects, by the end of the forecast period, new branded therapies Vyxeos, volasertib and CC-486 will dominate the market along with generic azacitidine. The AML pipeline is weak in terms of efficacy; however, GlobalData expects none of these drugs to have a major impact on the overall AML market. The challenge for new entrants into the AML market is to meet the critically high unmet needs of AML patients and improve overall survival. One of the opportunities for the companies is to work cooperatively to develop therapies that work in combination with chemotherapy backbone.
Scope
Overview of AML, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
Annualized AML therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments (including, young patients, elderly patients, refractory/relapsed patients and FLT3 mutated patients), forecast from 2014 to 2024.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AML therapeutics market
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidate in Phase III development is profiled.
Analysis of the current and future market competition in the global AML therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Source: https://www.kenresearch.com/qatar-healthcare-industry-research-report-428.html
Contact:
Ken Research
Ankur Gupta,
Head Marketing & Communications
query@kenresearch.com
+91-124- 4230204
www.kenresearch.com
